Geode Capital Management increased its stake in Ligand Pharmaceuticals and filed required reports with the SEC.
1 report, 1 independent
Updated Jul 9
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Geode Capital Management increased its stake in Ligand Pharmaceuticals and filed required reports with the SEC.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Geode Capital Management
American Investment Management firm based in Boston, Massachusetts
-
Ligand Pharmaceuticals
biopharmaceutical company based out of La Jolla, California
Nothing else this week.
-
SEC
Slovak company
Related events
- Cboe Global Markets, Inc. filed a company disclosure with the SEC on October 25, 2026.
- Geode Capital Management raised its position in shares, while MarketBeat reported average stock ratings.
- Monopar Therapeutics stock traded on the Nasdaq exchange and disclosed transactions via SEC filings on October 5, 2026.
- Stock trades occurred on the NYSE platform while filing disclosures with the SEC.
- LuxExperience disclosed a stock transaction in an SEC filing on October 8, 2026.